Pattern Bioscience appoints David Barreca as Vice President of Sales. Commercial leader in diagnostics joins Pattern to build US sales organization as the company nears FDA submission of its breakthrough single-cell microbiology platform and launch of the Pneumonia ID/AST Panel. AUSTIN, Texas, July 27, 2026 - Pattern Bioscience, an innovator in rapid diagnostic technologies for bacterial infections, today announced the appointment of David Barreca as Vice President of Sales. Barreca joins as Pattern moves from clinical development toward FDA submission and commercial launch of its single-cell microbiology platform and first assay, the Pneumonia ID/AST Panel, and begins building the team that will bring its technology to clinical laboratories nationwide. Barreca brings more than 17 years of commercial diagnostics experience, with a career defined by building high-performing sales teams at innovative diagnostic startups. He recently built and led sales efforts for VITEK REVEAL at bioMérieux, following the company's acquisition of Specific Diagnostics in 2022, where he served as Vice President of Sales, and previously was Senior Director of Sales at GenMark Diagnostics ahead of its $1.8 billion acquisition by Roche in 2021. "Twice now, David has built the commercial teams that brought transformative microbiology platforms to market. As we approach FDA submission for our launch assay, David brings both discipline in building a sales organization and the credibility in the microbiology community to help our platform bring results to patients and clinicians," said Carey-Ann Burnham, PhD, Chief Executive Officer of Pattern Bioscience. Pattern's single-cell microbiology platform is the first and only culture-free, rapid phenotypic identification and susceptibility testing (ID/AST) platform designed to deliver clinically actionable results in hours, rather than the days required by traditional culture-based methods. The company recently shared new data across multiple presentations at ASM Microbe 2026. "I've spent my career bringing new microbiology diagnostics to market, and I've seen how long the field waits for tools that truly change patient care. Pattern is doing something genuinely different: combining ID, AST, and culture-level insight in a single, culture-free test, and delivering it in a fraction of the time. Joining right before launch is the kind of opportunity that doesn't come often, and I can't wait to get this platform into the hands of labs and clinicians," said David Barreca, Vice President of Sales at Pattern Bioscience. About Pattern Bioscience Pattern Bioscience aims to save lives by transforming how bacterial infections are diagnosed and improving global health by reducing the burden of antibiotic resistance. Its single-cell microbiology technology is the first and only culture-free, rapid phenotypic testing platform to deliver clinically actionable results in hours, compared to the days required by traditional culture-based methods. Pattern Bioscience is a privately held company based in Austin, Texas, and is led by veterans of the diagnostic industry with deep experience bringing new diagnostic technologies to market. For more information, visit pattern.bio. Forward-Looking Statements This press release contains forward-looking statements regarding Pattern Bioscience's product development, regulatory plans, and commercialization timeline, including statements about the Pneumonia ID/AST Panel and anticipated FDA submission and commercial launch. These statements are subject to risks and uncertainties, and actual results may differ materially. Pattern Bioscience's products are for Investigational Use Only; the performance characteristics of these products have not been established, and the products have not been cleared or approved by the FDA. Media Contact Kyle Fieleke

Pattern Bioscience has raised $43 million in Series D funding, led by AMR Action Fund, Illumina Ventures, and Omnimed Capital. The funds will support a US multi-center clinical trial and regulatory submission for their Pneumonia ID/AST Panel, which has FDA Breakthrough Device Designation and is backed by a BARDA contract worth up to $40.9 million. Latham & Watkins LLP represented Pattern Bioscience in the transaction.